CONTEMPORARY EPIGENETIC EVIDENCE ON THE SYSTEMIC PHENOTYPE OF RHEUMATIC DISEASE: FETUIN-A, TLR4 AND MICRORNA MARKERS
Litsenziya: cc-by
Annotatsiya
Aim. To assess, in an integrated analysis, the clinical, diagnostic and prognostic value of two epigenetically regulated biomarker systems - the hepatokine fetuin-A together with the innate immune receptor TLR4, and the microRNA-122/-221 profile - across the articular and the systemic (extra-articular) course of rheumatoid arthritis (RA). Materials and methods. Two complementary datasets were analysed comparatively. Cohort 1 comprised 140 patients with RA classified by the 2010 ACR/EULAR criteria (articular form, n = 86; extra-articular form, n = 54) and 36 healthy controls; serum fetuin-A and TLR4 were measured by sandwich ELISA. Cohort 2 comprised 148 patients with RA and comorbid chronic diffuse liver disease of differing aetiology (chronic viral hepatitis, n = 21; RA with non-alcoholic fatty liver disease, n = 46; RA with secondary or drug-induced liver injury, n = 81) and 20 healthy controls; circulating microRNA-122 and microRNA-221 were quantified by reverse-transcription real-time PCR. Within cohort 1, each clinical form was randomised to standard basic therapy or to the same regimen plus ademetionine (subgroups 1A/1B, n = 43 each; 2A/2B, n = 27 each), with reassessment after three months. Analyses were performed in SPSS Statistics 26.0 and STATISTICA 12.0 using the t test, one-way ANOVA, the χ² test, Pearson and Spearman correlation, multivariable regression and ROC analysis. Results. Serum fetuin-A in RA was 2.08-fold lower than in controls (787.33 ± 195.71 vs 1640.2 ± 215.8 ng/mL; p < 0.001) and TLR4 was 2.33-fold higher (11.23 ± 2.30 vs 4.81 ± 1.42 ng/mL; p < 0.001). The two markers were inversely correlated (r = −0.624; p < 0.001), and the association was stronger in the extra-articular form (r = −0.672) than in the articular form (r = −0.548). Used together, fetuin-A and TLR4 identified high disease activity with an AUC of 0.872 (95% CI 0.818–0.926), exceeding either marker alone (AUC 0.768 and 0.792) by 0.080–0.104 in absolute terms. Among patients with comorbid liver disease, the distribution of microRNA-122 and microRNA-221 expression differed significantly across the three aetiological subgroups (χ² = 8.0, p < 0.005 and χ² = 5.9, p < 0.01) and was associated with the ultrasonographic stage of liver fibrosis, with disease duration rather than aetiology as the dominant determinant. Over three months, adding ademetionine produced a 1.95-fold and 1.74-fold greater recovery of fetuin-A and a 1.65-fold and 1.47-fold greater fall in TLR4 than standard therapy alone in the articular and extra-articular groups respectively (all p < 0.001), and raised EULAR good response from 20.93% to 41.86% (χ² = 4.12; p = 0.04) and from 14.81% to 40.74% (χ² = 4.80; p = 0.03). Receipt of ademetionine was an independent predictor of good response (OR = 4.32; 95% CI 1.86–10.04). Conclusion. The fetuin-A/TLR4 axis and the microRNA-122/-221 profile together describe the systemic phenotype of RA and the hepatic involvement that accompanies it, linked through a shared IL-6/TNF-α–NF-κB/STAT3 pathway. Monitoring both systems supports earlier recognition of the extra-articular phenotype and a more individualised treatment strategy.
Hali tarjima qilinmagan